Showing 1147 results
- https://www.novartis.com/news/media-releases/sandoz-strengthens-pipeline-expansion-through-partnership-develop-and-manufacture-multiple-biosimilarsSandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansionSandoz gains access to proprietary AI-driven technology platform…
- https://www.novartis.com/news/media-releases/new-sandoz-board-directors-appointedNovartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2…
- https://www.novartis.com/news/media-releases/sandoz-exclusively-commercialize-six-products-us-reinforcing-global-leadership-position-patent-medicinesAgreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology.Products from Adalvo slated for near- to mid-term launches, with four out of six…
- https://www.novartis.com/news/media-releases/novartis-feature-new-pnh-and-cml-scientific-data-from-broad-hematology-portfolio-european-hematology-association-annual-meetingUpdated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studiesHead-to-head data from Phase III ASCEMBL trial…
- https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-4Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg…
- https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-annuelle-1Les actionnaires approuvent la 24e augmentation consécutive du dividende qui passe à CHF 3.– (+1,7%) par action pour l’année 2020, soit un rendement de 3,8%1 et une distribution du free cash-flow d’…
- https://www.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda-0Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (…
- https://www.novartis.com/news/media-releases/new-peer-reviewed-research-shows-no-increased-risk-serious-covid-19-infections-kesimpta-ofatumumab-treated-adults-multiple-sclerosisThe study published in ‘Neurology and Therapy’ also shows the fatal outcomes and hospitalization rates due to COVID-19 in those treated with Kesimpta were in line with the rates in the general MS…
- https://www.novartis.com/news/media-releases/sandoz-marketing-authorization-applications-proposed-biosimilar-denosumab-accepted-emaSubmissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for…
- https://www.novartis.com/news/media-releases/novartis-continue-le-fort-elan-des-principales-marques-de-croissance-progresse-dans-ses-initiatives-strategiques-et-confirme-les-previsions-de-lexercice-2022-pour-le-groupeAnnonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T2 en hausse de +5% tcc1(-1% USD) Innovative Medicines (IM): hausse du chiffre d’affaires de +5% (tcc, -1% USD), avec…